Hospitals are more likely than medical groups and physician management companies to acquire unprofitable physician practices, according to a recent survey released in "The 1997-1998 Physician Practice Acquisition Resource Book."
Hospitals are more likely than medical groups and physician management companies to acquire unprofitable physician practices, according to a recent survey released in "The 1997-1998 Physician Practice Acquisition Resource Book."
The survey, conducted by The Center for Health Care Industry Performance Studies, draws its conclusions from 460 physician practice acquisitions made between 1994 and 1996. It represents more than 1,200 physicians from numerous specialties.
According to William Cleverly, Ph.D., who co-wrote the book with Patrick Knott and Carson Dye, there are several reasons why hospitals may acquire unprofitable physician practices.
"First, hospitals tend to pay higher salaries to employed physicians than other firms do, and second, hospital management may believe there are substantial opportunities to raise practice revenues or decrease costs to make the practices more profitable," Cleverly said.
But a third reason, according to the authors, may be the substantial opportunities for additional referral revenue for the hospital. "This strategy is, of course, illegal," Cleverly said.
The survey also uncovered a misperception about physician practice acquisitions. While it is generally assumed that tangible assets - accounts receivable, property and equipment - make up only a small percentage of a total purchase price, survey results indicated that the percentage is actually much higher than previously believed. PR
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.